August 10, 2021

Sydnexis Executes Exclusive License with Santen

Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation, for Europe, Middle East and Africa.

Read More

August 10, 2021

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Bluestem Capital

Sydnexis today announced the completion of a $45 million Series B financing led by Visionary Ventures, Bluestem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Read More

August 10, 2021

Sydnexis Executes Exclusive License with Santen

Santen SA and Sydnexis Inc. announce the signing of an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation, for Europe, Middle East and Africa.

Read More

August 10, 2021

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Bluestem Capital

Sydnexis today announced the completion of a $45 million Series B financing led by Visionary Ventures, Bluestem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Read More